Home > A. Molecular pathology > Signaling pathways > MAPK signaling pathway
MAPK signaling pathway
Wednesday 11 June 2003
MAPK Pathway
Members
ERK | BRAF | RAS | MAPKs |
MAPK pathway inhibitors
The MAPK pathway is a key therapeutic target for melanoma as it is activated in most tumors. Despite the clinical success of drugs targeting this pathway, their therapeutic efficacy is limited by the development of drug resistance. To develop effective therapies for melanoma, it is critical to uncover the mechanisms of resistance to BRAF inhibitors and MEK inhibitors. Recent studies on the molecular mechanisms of resistance to inhibitors of the MAPK pathway and potential strategies to overcome resistance will be discussed.
See also
RASs: HRAS, KRAS, NRAS
References
Kim IA, Fernandes AT, Gupta AK, McKenna WG, Bernhard EJ. The influence of Ras pathway signaling on tumor radiosensitivity. Cancer Metastasis Rev. 2004 Aug;23(3-4):227-36. PMID: 15197325
Downward J. Targeting RAS signalling pathways in cancer therapy. Nat Rev Cancer. 2003 Jan;3(1):11-22. PMID: 12509763
Stork PJ, Schmitt JM. Crosstalk between cAMP and MAP kinase signaling in the regulation of cell proliferation. Trends Cell Biol. 2002 Jun ;12(6):258-66. PMID : 12074885
Hazzalin CA, Mahadevan LC. MAPK-regulated transcription: a continuously variable gene switch? Nat Rev Mol Cell Biol. 2002 Jan;3(1):30-40. PMID: 11823796
Madhani HD, Fink GR. The riddle of MAP kinase signaling specificity. Trends Genet. 1998 Apr;14(4):151-5. PMID: 9594663
Breitkreutz A, Tyers M. MAPK signaling specificity : it takes two to tango. Trends Cell Biol. 2002 Jun ;12(6):254-7. PMID : 12074884
Animation of the organisation and function of the Ras-Raf-MEK-ERK pathway at Expert Reviews in Molecular Medicine